Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
70.58
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
July 06, 2023
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers
Via
InvestorPlace
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
July 06, 2023
BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles.
Via
MarketBeat
Exposures
Product Safety
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
July 03, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 14, 2023
Via
Benzinga
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
July 05, 2023
BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
July 05, 2023
Via
Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
June 30, 2023
On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults
Via
Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
June 30, 2023
New York Post
Via
Benzinga
Death Cross Looms Over Biomarin Pharmaceutical Investors
May 02, 2023
Via
Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
June 30, 2023
The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency...
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
June 22, 2023
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.
Via
InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
June 20, 2023
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of...
Via
SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
April 27, 2023
Via
Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
April 25, 2023
Via
Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
March 21, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
May 26, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 25, 2023
Via
Benzinga
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
May 17, 2023
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
April 20, 2023
Via
Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.
Via
InvestorPlace
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
March 28, 2023
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story.
Via
The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
March 21, 2023
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
March 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.